Syncope and Related Paroxysmal Spells

Back

Author

Roy Sucholeiki, MD, Director, Comprehensive Seizure and Epilepsy Program, The Neurosciences Institute at Central DuPage Hospital

UCB Pharma Honoraria Speaking and teaching

Specialty Editor(s)

Florian P Thomas, MD, MA, PhD, Drmed, Director, Spinal Cord Injury Unit, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, and Department of Molecular Microbiology and Immunology, St Louis University

Nothing to disclose.

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine

Nothing to disclose.

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital

Nothing to disclose.

Spiros Manolidis, MD, Associate Professor of Otolaryngology and Neurological Surgery, Columbia University

Nothing to disclose.

Chief Editor

Robert A Egan, MD, Director of Neuro-Ophthalmology, St Helena Hospital

Nothing to disclose.

Background

Syncope is a term used to describe the loss of consciousness from temporary disruption of cerebral oxygenation. This is typically due to the interruption of blood flow to the brain, and the loss of consciousness usually lasts for less than 30 seconds. In lay terms, fainting is the equivalent descriptive term.

Patients who complain of dizziness, light-headedness, passing out, and/or blacking out must be questioned carefully to determine whether a true syncopal event has occurred. Other spells (eg, seizure, transient ischemic attack, cataplexy) may be similar, and a careful history often can clarify the condition and guide further evaluation and care. Syncope is a symptom of either cardiac or hemodynamic dysfunction and not a disease (or diagnosis).

Pathophysiology

The causes of syncope are many (see Causes). The 3 most important broad categories are the following: (1) decreased cardiac output secondary to intrinsic cardiac disease or clinically significant blood or volume loss; (2) decreased peripheral vascular resistance and/or venous return; and (3) clinically significant cerebrovascular disease that leads to compromise of cerebral perfusion. Regardless of the cause, all of these categories share a common factor, namely, disruption of adequate cerebral oxygenation resulting in a transient alteration of consciousness.

Epidemiology

Frequency

United States

Syncope is common. However, exact rates are difficult to cite because of the many potential causes and varying history of the symptoms. Syncope accounts for 1-6% of admissions to hospitals and 1-3% of visits to emergency departments.

Mortality/Morbidity

Age

Syncope can occur in any age group, but the etiology varies by age. A young individual may have a syncopal attack with blood loss, dehydration, or hypoglycemia. Although these problems can occur in older individuals, additional medical problems could potentiate syncope. These problems may include congestive heart failure, autonomic instability, valvular heart disease, and cerebrovascular disease.

History

Regardless of the cause, patients with syncope present in a similar fashion. Vertigo is not a typical symptom of syncope. By definition, vertigo requires a sensation of spinning or movement that may indicate a cerebellar or vestibular problem. When patients use the term dizziness, the physician should thoroughly question the patient to clarify the symptom. The word dizzy or dizziness is ambiguous, and people can have vastly different meanings.

Physical

Because syncope is, by definition, a transient event, the general physical findings on initial presentation are usually normal. However, the following abnormalities can be noted:

Causes

Syncope has many potential causes, some of which are challenging to diagnose.

Laboratory Studies

Imaging Studies

Other Tests

Medical Care

Consultations

Consultation with a specialist may be appropriate.

Diet

In cases of chronic orthostatic hypotension, altering the diet by adding salt to encourage volume expansion may be helpful.

Activity

Medication Summary

Pharmacotherapy is indicated when presyncope or syncope is recurrent and refractory to nonpharmacologic treatment. The choice of medication depends on the cause and the severity of the orthostatic hypotension in particular. Various medications for associated comorbidities, such as diabetes, hypertension, and cardiac abnormalities, may indirectly improve some symptoms of syncope.

Class Summary

These agents have anti-inflammatory properties and cause profound and varied metabolic effects.

Fludrocortisone (Florinef)

Clinical Context:  Synthetic steroid with predominantly mineralocorticoid activity. Primary effects on renal distal tubules to enhance sodium reabsorption; also increases urinary excretion of potassium and hydrogen ions. Primary effects and similar actions on cation transport in other tissues appear to account for the spectrum of physiologic activities of mineralocorticoids. Maintains intravascular and extracellular volume. Available only as tab, which may be crushed.

For patients requiring parenteral mineralocorticoid therapy, high-dose hydrocortisone must be used. Dose determined by measuring BP (hypertension indicates overreplacement) and supine plasma renin activity (PRA). PRA suppression indicates overreplacement and elevation indicates underreplacement. Dosages vary considerably (50-500 mcg/d) and must be individualized. Dose adjustment typically not required in acute illness, though some advocate increasing dose in severe GI illness.

Class Summary

These agents improve the patient's hemodynamic status by increasing myocardial contractility and heart rate, increasing cardiac output. They also increase peripheral resistance by causing vasoconstriction. Increased cardiac output and increased peripheral resistance lead to increased BP.

Midodrine (ProAmatine)

Clinical Context:  Increases standing, sitting, and supine systolic and diastolic BP in patients with orthostatic hypotension of various etiologies. Standing systolic BP elevated by approximately 15-30 mm Hg at 1 h after 10-mg dose, with some effect for 2-3 h. No clinically significant effect on standing or supine pulse rates in patients with autonomic failure.

Clonidine (Catapres)

Clinical Context:  Central alpha-adrenergic agonist that stimulates alpha2-adrenoreceptors in brainstem and activates inhibitory neuron, decreasing vasomotor tone and heart rate. Used to control symptomatic hypertension; suggested if diastolic hypertension (>85 mm Hg) persists 30 min after diazepam administration.

References

  1. Bajwa S, Stewart JA, Treadwell S, Lakhani DR. Swallow syncope: reflex or reflux?. Postgrad Med J. Mar 2008;84(989):160-2.[View Abstract]
  2. Adams RD, Victor M, Ropper AH. Faintness and syncope. In: Adams RD, Victor M, Ropper AH, eds. Principles of Neurology. New York, NY: McGraw-Hill; 1997:367-79.
  3. Axelrod FB, Goldberg JD, Rolnitzky L, et al. Fludrocortisone in patients with familial dysautonomia--assessing effect on clinical parameters and gene expression. Clin Auton Res. Aug 2005;15(4):284-91.[View Abstract]
  4. Carinci V, Barbato G, Baldrati A, Di Pasquale G. Asystole induced by partial seizures: a rare cause of syncope. Pacing Clin Electrophysiol. Nov 2007;30(11):1416-9.[View Abstract]
  5. Claydon VE, Hainsworth R. Salt supplementation improves orthostatic cerebral and peripheral vascular control in patients with syncope. Hypertension. Apr 2004;43(4):809-13.[View Abstract]
  6. Drislane FW, Feske S. Transient events. In: Samuels MA, Feske S, et al, eds. Office Practice of Neurology. New York, NY: Churchill-Livingstone; 1996:111-4.
  7. Eagle KA, Black HR, Cook EF, Goldman L. Evaluation of prognostic classifications for patients with syncope. Am J Med. Oct 1985;79(4):455-60.[View Abstract]
  8. Farrehi PM, Santinga JT, Eagle KA. Syncope: diagnosis of cardiac and noncardiac causes. Geriatrics. Nov 1995;50(11):24-30.[View Abstract]
  9. Farwell DJ, Freemantle N, Sulke N. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J. Feb 2006;27(3):351-6.[View Abstract]
  10. Gould PA, Krahn AD, Klein GJ, et al. Investigating syncope: a review. Curr Opin Cardiol. Jan 2006;21(1):34-41.[View Abstract]
  11. Jarjour IT, Jarjour LK. Low iron storage in children and adolescents with neurally mediated syncope. J Pediatr. Jul 2008;153(1):40-4.[View Abstract]
  12. Jiménez D, Diaz G, Valle M, et al. [Prognostic value of syncope in the presentation of pulmonary embolism]. Arch Bronconeumol. Jul 2005;41(7):385-8.[View Abstract]
  13. Kapoor W, Snustad D, Peterson J, et al. Syncope in the elderly. Am J Med. Mar 1986;80(3):419-28.[View Abstract]
  14. Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med. Jul 28 1983;309(4):197-204.[View Abstract]
  15. Kokturk N, Oguzulgen IK, Demir N, et al. Differences in clinical presentation of pulmonary embolism in older vs younger patients. Circ J. Aug 2005;69(8):981-6.[View Abstract]
  16. Lipsitz LA, Wei JY, Rowe JW. Syncope in an elderly, institutionalised population: prevalence, incidence, and associated risk. Q J Med. Apr 1985;55(216):45-54.[View Abstract]
  17. Mabuchi N, Hirayama M, Koike Y, et al. Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy. J Neurol Neurosurg Psychiatry. Jul 2005;76(7):947-52.[View Abstract]
  18. Medical Economics. Physician's Desk Reference. 53rd ed. Montvale, NJ: Medical Economics; 1999.
  19. Pérez Riera AR, Antzelevitch C, Schapacknik E, et al. Is there an overlap between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy/dysplasia?. J Electrocardiol. Jul 2005;38(3):260-3.[View Abstract]
  20. [Best Evidence] Quinn J, McDermott D, Kramer N, Yeh C, Kohn MA, Stiell I, et al. Death after emergency department visits for syncope: how common and can it be predicted?. Ann Emerg Med. May 2008;51(5):585-90.[View Abstract]